Prescient Therapeutics Ltd

ASX:PTX ISIN:AU000000PTX3

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 
 
           

Sprache wählen

News

Australischer Marktbericht, 14. Februar 2011: Black Fire Minerals (ASX:BFE) erwirbt Wolfram-/Kupferprojekt in den USA

🕔2/14/2011 12:20:00 PM 16705

Australischer Marktbericht, 14. Februar 2011 beinhaltet: Black Fire Minerals Limited (ASX:BFE) erwirbt 100% des fortgeschrittenen Pilot Mountain Wolfram-/Kupferprojekts in Nevada (USA); Virax Holdings Limited (ASX:VHL) entwickelt ein neuartiges Produkt für die Behandlung von Hautkrebs; Southern Cross Goldfields Limited (ASX:SXG) entdeckte eine oberflächennahe hochwertige Gold-Lagerstätte in Western Australia; Prosperity Resources Limited (ASX:PSP) hat mit den Bohrungen nach Gold in Indonesien begonnen.

Lesen Sie die komplette Artikel
###

140,950 COMPANY PROFILE VIEWS

  • Diese Seite wurde besucht: (letzten 7 Tagen: 21) (letzten 30 Tagen: 91) (seit Veröffentlichung: 11193) 

Company Data

    Fax
  • (03) 9853 5134 
  • Principal Sector
  • Gesundheit & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.virax.com.au/

More News Results

  • 2025/07/04: Prescient Share Purchase Plan Investor Presentation*
  • 2025/07/02: Prescient Therapeutics Opens Share Purchase Plan*
  • 2025/07/02: Share Purchase Plan Cleansing Notice*
  • 2025/07/01: Proposed issue of securities - PTX*
  • 2025/07/01: Prescient Therapeutics Launches Share Purchase Plan for $7m*
  • 2025/06/02: Change of Registered Office and Principal Place of Business*
  • 2025/05/29: PTX Updated Investor Presentation*
  • 2025/05/27: First Patient dosed for PTX-100 Phase 2a Study*
  • 2025/05/21: Prescient Therapeutics - Investor Briefing*
  • 2025/05/06: Change of Director's Interest Notice*
*refer to company website